1. (currently amended) A method of treating a mammal having precancerous lesions comprising administering a pharmacologically effective amount of a compound of the following formula or pharmaceutically acceptable salt thereof:

$$\begin{array}{c|c}
 & O \\
 & N \\
 & N \\
 & R^2
\end{array}$$

$$\begin{array}{c|c}
 & N \\
 & H \\
 & A \\
 & n \\
 & R^3$$

wherein $[R_1 \text{ is}] \frac{R^1 \text{ is}}{R^1 \text{ is}}$ a hydrogen atom or a halogen atom;

[R₂ is] R² is a phenyl-lower alkyl group;

[R₃ is] R³ is a heterocyclic group selected from the group consisting of an indolyl group, indolinyl group, 1H-indazolyl group, 2(1H)-quinolinonyl group, 3,4dihydro-2(lH)-quinolinonyl group and 3,4-dihydro-1,4(2H)-benzoxazinyl group, said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a group of the formula -B-R⁴, (wherein B is a lower alkylene group; R⁴ is a 5-to 11membered saturated or unsaturated heterocyclic group of single ring or binary ring, having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, (said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and oxo group) or a group of the formula -NR⁵R⁶ (wherein R⁵ and R⁶ are each the same or different, and a hydrogen atom, a lower alkyl group, a cycloalkyl group, a pyridylcarbonyl group, an isoxazolylcarbonyl group which may have 1 to 3 lower alkyl groups as the substituents, a pyrrolylcarbonyl group or an amino-substituted lower alkyl group which may have a lower alkyl group as the substituent; further R⁵ and R⁶ may form 5- to 6-membered saturated heterocyclic group by combining to each other, together with the adjacent nitrogen atom being bonded thereto, further with or without other nitrogen atom or oxygen atom; said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a hydroxy group and a phenyl group); a lower alkenyl group; a lower alkoxycarbonyl group; a phenoxy-lower alkyl group which may have cyano group as the substituents; a halogen-substituted lower alkyl group; and a lower alkoxycarbonylsubstituted lower alkyl group;

A is a lower alkylene group; and n is 0 or 1.

Claim 2. (currently amended) The method according to Claim 1, wherein R³ is an indolyl group, said indolyl group may have 1 to 3 substituents selected from the group consisting of: a group of the formula -B-R⁴, (wherein B is a lower alkylene group; R⁴ is a 5- to 11-membered saturated or unsaturated heterocyclic group of single ring or binary ring, having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, (said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and oxo group) or a group of the formula -NR⁵R⁶ (wherein R⁵ and R⁶ are each the same or different, and a hydrogen atom, a lower alkyl group, a cycloalkyl group, a pyridylcarbonyl group, an isoxazolylcarbonyl group which may have 1 to 3 lower alkyl groups as the substituents, a pyrrolylcarbonyl group or an amino-substituted lower alkyl group which may have a lower alkyl group as the substituent; further R⁵ and R⁶ may form 5- to 6membered saturated heterocyclic group by combining to each other, together with the adjacent nitrogen atom being bonded thereto, further with or without other nitrogen atom or oxygen atom; said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a hydroxy group and a phenyl group) [group))]; a lower alkenyl group; a lower alkoxycarbonyl group; a phenoxy-lower alkyl group which may have cyano group as the substituents; a halogen-substituted lower alkyl group; and a lower alkoxycarbonyl-substituted lower alkyl group.

Claim 3. (currently amended) A method for inhibiting the growth of neoplastic cells comprising exposing the cells to a growth inhibiting effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof:

<u>(I)</u>

wherein $[R_1 \text{ is}] \underline{R^1 \text{ is}}$ a hydrogen atom or a halogen atom; $[R_2 \text{ is}] R^2 \text{ is a phenyl-lower alkyl group;}$

 $[R_3 \text{ is}] \underline{R^3 \text{ is}}$ a heterocyclic group selected from the group consisting of an indolyl group, indolinyl group, 1H-indazolyl group, 2(1H)-quinolinonyl group, 3,4dihydro-2(lH)-quinolinonyl group and 3,4-dihydro-1,4(2H)-benzoxazinyl group, said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a group of the formula -B-R⁴, (B is a lower alkylene group; R⁴ is a 5-to 11-membered saturated or unsaturated heterocyclic group of single ring or binary ring, having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, (said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and oxo group) or a group of the formula -NR⁵R⁶ (R⁵ and R⁶ are each the same or different, and a hydrogen atom, a lower alkyl group, a cycloalkyl group, a pyridyl-carbonyl group, an isoxazolylcarbonyl group which may have 1 to 3 lower alkyl groups as the substituents, a pyrrolylcarbonyl group, or an amino-substituted lower alkyl group which may have a lower alkyl group as the substituent; further R⁵ and R⁶ may form 5- to 6-membered saturated heterocyclic group by combining to each other, together with the adjacent nitrogen atom being bonded thereto, further with or without other nitrogen atom or oxygen atom; said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a hydroxy group and a phenyl group)); a lower alkenyl group; a lower alkoxycarbonyl group; a phenoxy-lower alkyl group which may have cyano group as the substituents; a halogen-substituted lower alkyl group; and a lower alkoxycarbonyl-substituted lower alkyl group;

A is a lower alkylene group; and n is 0 or 1.

Claim 4. (currently amended) The method according to Claim 3, wherein R³ is an indolyl group, said indolyl group may have 1 to 3 substituents selected from the group consisting of: a group of the formula -B-R¹, (B is a lower alkylene group; R⁴ is a 5- to 11-membered saturated or unsaturated heterocyclic group of single ring or binary ring, having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen

atom and sulfur atom, (said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and oxo group) or a group of the formula -NR⁵R⁶ (wherein R⁵ and R⁶ are each the same or different, and a hydrogen atom, a lower alkyl group, a cycloalkyl group, a pyridyl-carbonyl group, an isoxazolylcarbonyl group which may have 1 to 3 lower alkyl groups as the substituents, a pyrrolylcarbonyl group or an amino-substituted lower alkyl group which may have a lower alkyl group as the substituent; further R⁵ and R⁶ may form 5- to 6membered saturated heterocyclic group by combining to each other, together with the adjacent nitrogen atom being bonded thereto, further with or without other nitrogen atom or oxygen atom; said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a hydroxy group and a phenyl [group))] group); a lower alkenyl group; a lower alkoxycarbonyl group; a phenoxy-lower alkyl group which may have cyano group as the substituents; a halogen-substituted lower alkyl group; and a lower alkoxycarbonyl-substituted lower alkyl group.

Claim 5. (currently amended) A method for regulating apoptosis in human cells comprising exposing said cells to an effective amount of a compound of the formula:

$$\begin{array}{c|c}
 & O \\
 & N \\
 & N \\
 & R^2
\end{array}$$

$$\begin{array}{c|c}
 & N \\
 & H
\end{array}$$

$$\begin{array}{c|c}
 & A \\
 & n \\
 & R^3
\end{array}$$

wherein $[R_1 \text{ is}] \underline{R^1 \text{ is}}$ a hydrogen atom or a halogen atom;

 $[R_2 \text{ is}] \frac{R^2 \text{ is}}{R^2 \text{ a phenyl-lower alkyl group;}}$

[R₃ is] R³ is a heterocyclic group selected from the group consisting of an indolyl group, indolinyl group, 1H-indazolyl group, 2(1H)-quinolinonyl group, 3,4-dihydro-2(lH)-quinolinonyl group and 3,4-dihydro-1,4(2H)-benzoxazinyl group, said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a group of the formula -B-R⁴, ([.a] wherein B is a lower alkylene group; R⁴ is a 5-to 11-membered saturated or unsaturated heterocyclic group of single ring or binary ring, having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, (said heterocyclic group may have 1 to 3 substituents selected from

the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and oxo group) or a group of the formula -NR⁵R⁶ (wherein R⁵ and R⁶ are each the same or different, and each is a hydrogen atom, a lower alkyl group, a cycloalkyl group, a pyridyl-carbonyl group, an isoxazolylcarbonyl group which may have 1 to 3 lower alkyl groups as the substituents, a pyrrolylcarbonyl group, or an amino-substituted lower alkyl group which may have a lower alkyl group as the substituent; further R⁵ and R⁶ may form 5- to 6-membered saturated heterocyclic group by combining to each other, together with the adjacent nitrogen atom being bonded thereto, further with or without other nitrogen atom or oxygen atom; said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a hydroxy group and a phenyl [group))] group); a lower alkenyl group; a lower alkoxycarbonyl group; a phenoxy-lower alkyl group which may have cyano group as the substituents; a halogen-substituted lower alkyl group; and a lower alkoxycarbonyl-substituted lower alkyl group;

A is a lower alkylene group; and n is 0 or 1.

Claim 6. (currently amended) The method according to Claim 5, wherein R³ is an indolyl group, said indolyl group may have 1 to 3 substituents selected from the group consisting of: a group of the formula -B-R⁴, (wherein B is a lower alkylene group; R⁴ is a 5- to 11-membered saturated or unsaturated heterocyclic group of single ring or binary ring, having 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, oxygen atom and sulfur atom, (said heterocyclic group may have 1 to 3 substituents selected from the group consisting of a halogen atom, a lower alkyl group, a lower alkoxy group and oxo group) or a group of the formula -NR⁵R⁶ (wherein R⁵ and R⁶ are each the same or different, and each is a hydrogen atom, a lower alkyl group, a cycloalkyl group, a pyridylcarbonyl group, an isoxazolylcarbonyl group which may have 1 to 3 lower alkyl groups as the substituents, a pyrrolylcarbonyl group or an amino-substituted lower alkyl group which may have a lower alkyl group as the substituent; further R⁵ and R⁶ may form 5- to 6membered saturated heterocyclic group by combining to each other, together with the adjacent nitrogen atom being bonded thereto, further with or without other nitrogen atom or oxygen atom; said heterocyclic group may have 1 to 3 substituents selected from

P-168-1 10/003,868 H.V. Owens, Jr.

the group consisting of a hydroxy group and a phenyl [group))] group); a lower alkenyl group; a lower alkoxycarbonyl group; a phenoxy-lower alkyl group which may have cyano group as the substituents; a halogen-substituted lower alkyl group; and a lower alkoxycarbonyl-substituted lower alkyl group.